Other News To Note.

* Aileron Therapeutics, of Cambridge, Mass., and Roche Holdings AG, of Basel, Switzerland, expanded their collaboration to develop and commercialize stapled peptide drugs. The potential $1.1 billion drug development collaboration, launched in August 2010, encompassed up to five programs of strategic importance to Roche; initially Aileron launched the collaboration around two key programs in oncology. Aileron and Roche will now work on a third program in inflammatory diseases. Aileron also said it achieved a key milestone under the collaboration related to in vivo proof of concept, triggering a milestone payment. Financial terms were not disclosed. (See BioWorld Today, Aug. 31, 2010.) …